Key Takeaways
- • IM8, co-founded by David Beckham and health sciences company Prenetics, secured $1 billion in non-dilutive growth financing from General Catalyst's Customer Value Fund (CVF), with no equity stake transferred to the investor.
- • General Catalyst will fund 70% of IM8's marketing spend and receive a capped share of revenue generated only from customers acquired through the financing; after recovery of investment and returns, IM8 retains 100% of customer value going forward.
- • The financing structure represents a "third way" alternative to traditional dilutive equity raises or cash-constrained organic growth, purpose-built for customer acquisition repayment tied directly to cohort revenue performance.
- • IM8 raised full-year 2026 revenue guidance to $210–220 million (from $190–210 million) and expects to reach $300 million in revenue, currently operating at $17 million in monthly revenue.
- • Prenetics maintains $139.7 million in cash and assets, positioning the wellness brand to scale without traditional capital dilution or balance-sheet strain.
Summary
IM8, the wellness brand co-founded by former footballer David Beckham in partnership with health sciences company Prenetics, has closed a landmark $1 billion growth financing agreement with General Catalyst's Customer Value Fund (CVF). The deal is structured as non-dilutive capital, meaning General Catalyst acquires no equity stake in the company—a critical distinction that preserves founder control and company valuation structure.
Under the partnership terms, General Catalyst will fund 70% of IM8's customer acquisition marketing spend. The venture capital fund receives a capped share of revenue tied exclusively to customers acquired through this financing arrangement. Once General Catalyst recovers its initial investment and predetermined returns, IM8 gains full ownership of the ongoing customer value generated, creating an alignment-based revenue-sharing model rather than traditional equity dilution.
Prenetics characterized the CVF structure as addressing a structural problem faced by high-growth consumer businesses: the historical binary choice between raising dilutive equity capital or constraining growth to preserve cash reserves. The company emphasized that its rationale for accepting the financing was "structural rather than liquidity-driven," noting it currently holds $139.7 million in cash and assets. The CVF model functions as "no-dilution, risk-aligned, cohort-matched capital" explicitly designed to finance customer acquisition and is repaid only from revenue generated by those customers.
The financing comes as IM8 accelerates its growth trajectory. The company has raised full-year 2026 revenue guidance to $210–220 million, up from prior guidance of $190–210 million, and projects reaching $300 million in revenue. IM8 currently generates $17 million in monthly revenue, demonstrating significant operational scale within the wellness beverage and supplement category.
This deal underscores a broader trend in venture capital toward alternative financing structures that preserve founder equity while enabling aggressive customer acquisition spending in high-growth consumer brands. For IM8, the arrangement provides capital efficiency—enabling scaled marketing investment while maintaining full long-term economics on acquired customers after the fund's returns are satisfied.
Under the partnership terms, General Catalyst will fund 70% of IM8's customer acquisition marketing spend. The venture capital fund receives a capped share of revenue tied exclusively to customers acquired through this financing arrangement. Once General Catalyst recovers its initial investment and predetermined returns, IM8 gains full ownership of the ongoing customer value generated, creating an alignment-based revenue-sharing model rather than traditional equity dilution.
Prenetics characterized the CVF structure as addressing a structural problem faced by high-growth consumer businesses: the historical binary choice between raising dilutive equity capital or constraining growth to preserve cash reserves. The company emphasized that its rationale for accepting the financing was "structural rather than liquidity-driven," noting it currently holds $139.7 million in cash and assets. The CVF model functions as "no-dilution, risk-aligned, cohort-matched capital" explicitly designed to finance customer acquisition and is repaid only from revenue generated by those customers.
The financing comes as IM8 accelerates its growth trajectory. The company has raised full-year 2026 revenue guidance to $210–220 million, up from prior guidance of $190–210 million, and projects reaching $300 million in revenue. IM8 currently generates $17 million in monthly revenue, demonstrating significant operational scale within the wellness beverage and supplement category.
This deal underscores a broader trend in venture capital toward alternative financing structures that preserve founder equity while enabling aggressive customer acquisition spending in high-growth consumer brands. For IM8, the arrangement provides capital efficiency—enabling scaled marketing investment while maintaining full long-term economics on acquired customers after the fund's returns are satisfied.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.